Table of Contents

company-logo

Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing Liposomal Bcl-2 for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; Liposomal STAT3 that is in preclinical stage for the treatment of pancreatic cancer, non-small cell lung cancer, and AML; and prexigebersen-A for various solid tumors. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.

Bio-Path Dividend Announcement

• Bio-Path does not currently offer dividends, we're keeping a close eye on its growth potential and financial developments.
• Stay tuned for updates on Bio-Path dividend policy and future announcements. In the meantime, explore other dividend-yielding opportunities on our website.

Bio-Path Dividend History

Bio-Path Dividend Yield

Bio-Path current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing Bio-Path stock? Use our calculator to estimate your expected dividend yield:

Bio-Path Financial Ratios

P/E ratio-0.12
PEG ratio0.01
P/B ratio1.12
ROE-2842.40%
Payout ratio0.00%
Current ratio1.67
Quick ratio1.58
Cash Ratio1.33

Bio-Path Dividend FAQ

Does Bio-Path stock pay dividends?
Bio-Path does not currently pay dividends to its shareholders.
Has Bio-Path ever paid a dividend?
No, Bio-Path has no a history of paying dividends to its shareholders. Bio-Path is not known for its dividend payments.
Why doesn't Bio-Path pay dividends?
There are several potential reasons why Bio-Path would choose not to pay dividends to their shareholders:

1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.

2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.

3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.

4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.

5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Will Bio-Path ever pay a dividend?
The decision for a company to pay dividends depends on various factors including its financial performance, growth prospects, capital allocation priorities, and shareholder preferences. While Bio-Path has not paid dividends historically and has instead focused on reinvesting its earnings for growth, it's ultimately up to the company's management and board of directors to decide whether to initiate a dividend policy in the future.
Is Bio-Path a dividend aristocrat?
Bio-Path is not considered a Dividend Aristocrat. The term "Dividend Aristocrat" is typically used to describe a company in the S&P 500 index that has increased its dividend payouts for at least 25 consecutive years.
Is Bio-Path a dividend king?
Bio-Path is not classified as a "Dividend King". A Dividend King is a company that has managed to increase its dividend payouts for 50 consecutive years or more, which is an even more selective group than the Dividend Aristocrats.
Is Bio-Path a dividend stock?
No, Bio-Path is not considered a dividend stock. A dividend stock is a stock of a company that regularly pays out dividends to its shareholders.
How to buy Bio-Path stocks?
To buy Bio-Path you need a brokerage account. Open an account with a reputable brokerage firm that offers access to the stock market. Consider factors such as fees and account minimums.

Place an order: Use the brokerage's trading platform to place an order to buy Bio-Path stock.

Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.